Kintara Reports Positive Phase 2 Trial On Recurrent Glioblastoma Multiforme; Stock Surges

(RTTNews) - Kintara Therapeutics Inc. (KTRA) revealed a promising results from phase 2 clinical trial of VAL-083 for recurrent glioblastoma multiforme. The results provided important safety and efficacy data to support further evaluation of VAL-083 for the treatment of glioblastoma multiforme or GBM.

In Thursday pre-market trade, KTRA was trading at $2.87 up $0.60 or 26.43%.

The phase 2 trial is a two-arm, biomarker-driven study testing VAL-083 in glioblastom a multiforme or GBM patients who have an unmethylated promoter of the methylguanine DNA-methyltransferase (MGMT) gene.

As per the trial results, Median overall survival for the 48 efficacy evaluable patients initially receiving the treatment dose of 30 mg/m2/day is 8.0 months. Lomustine, which is the most commonly used chemotherapy for these patients, has demonstrated median overall survival of 7.2 months.

myelosuppression was the most common adverse event. In the 30 mg/m2/day starting dose cohort, five patients experienced a serious adverse event possibly related to VAL-083.

For the 83 efficacy evaluable patients who have completed at least one cycle of treatment median overall survival was 7.5 months.

Kintara noted that the study of VAL-083 continues in GBM AGILE, an adaptive registration study where it is currently the only therapeutic agent being evaluated for all three GBM patient subtypes: newly-diagnosed methylated MGMT, newly-diagnosed unmethylated MGMT, and recurrent.